Hartford Dialysis is a medicare approved dialysis facility center in Hartford, Connecticut and it has 27 dialysis stations. It is located in Hartford county at 675 Tower Avenue, Hartford, CT, 06112. You can reach out to the office of Hartford Dialysis at (860) 242-0735. This dialysis clinic is managed and/or owned by Davita. Hartford Dialysis has the following ownership type - Profit. It was first certified by medicare in October, 1999. The medicare id for this facility is 072516 and it accepts patients under medicare ESRD program.
Name | Hartford Dialysis |
---|---|
Location | 675 Tower Avenue, Hartford, Connecticut |
No. of Dialysis Stations | 27 |
Medicare ID | 072516 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | Yes |
675 Tower Avenue, Hartford, Connecticut, 06112 | |
(860) 242-0735 | |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
NPI Number | 1356317192 |
Organization Name | Hartford Dialysis |
Doing Business As | Dva Renal Healthcare Inc |
Address | 675 Tower Ave Hartford, Connecticut, 06112 |
Phone Number | (860) 242-0735 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 70% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 9% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 21% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 58% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 14% |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 61% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 16% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 23% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 12% |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 77% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 23% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 12% |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Dialysis patients with Hemoglobin data | 94 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 6 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 138 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 1380 |
Percentage of adult patients getting regular hemodialysis at the center | 98 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Adult patients getting regular peritoneal dialysis at the center | 22 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 200 |
Percentage of adult patients getting regular peritoneal dialysis at the center | 96 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Hartford Dialysis with elevated calcium levels.
Patients with hypercalcemia | 166 |
Hypercalcemia patient months | 1673 |
Patients with Serumphosphor | 178 |
Patients with Serumphosphor less than 3.5 mg/dL | 11 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 33 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 12 |
Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 112 |
Patient months included in arterial venous fistula and catheter summaries | 1069 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 62 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 134 |
Hospitalization Rate in facility | 136.7 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 218 |
Hospitalization Rate: Lower Confidence Limit | 92 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
The rate of readmission show you whether patients who were being treated regularly at Hartford Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 23.1 (As Expected) |
Readmission Rate: Upper Confidence Limit | 31 |
Readmission Rate: Lower Confidence Limit | 16.4 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Hartford Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | 2.26 (Worse than Expected) |
SIR: Upper Confidence Limit | 3.55 |
SIR: Lower Confidence Limit | 1.36 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Hartford Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 123 |
Transfusion Rate in facility | 21.4 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 47.1 |
Transfusion Rate: Lower Confidence Limit | 10.7 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
The rate of mortality show you whether patients who were being treated regularly at Hartford Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 723 |
Mortality Rate in facility | 16.1 (As Expected) |
Mortality Rate: Upper Confidence Limit | 19.9 |
Mortality Rate: Lower Confidence Limit | 12.8 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago
Hartford Hospital Location: 80 Seymour Street, Jb8, Hartford, Connecticut, 06102 Phone: (860) 972-2070 |
News Archive
Labopharm Inc. today announced that, through its wholly owned subsidiary, Labopharm Europe Limited, it has monetized the expected future royalty payment stream for RYZOLT(TM) (once-daily tramadol).
Donors at a replenishment meeting in New York on Tuesday pledged $11.7 billion over three years for the Global Fund to Fight AIDS, Tuberculosis and Malaria, "higher than past support but below the lowest target set by the agency in its efforts to combat disease in the developing world," the Financial Times reports.
One of the biggest problems in fighting breast cancer is the lack of inexpensive, early detection diagnostic tools.
Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.
MedImmune announced that it has initiated a pivotal head-to-head Phase 3 clinical trial designed to compare its next-generation, refrigerator- stable intranasal influenza vaccine (CAIV-T: cold adapted intranasal influenza vaccine, trivalent) with the injectable flu shot (TIV: trivalent influenza vaccine).
› Verified 7 days ago